Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31250412 | 1.00 | NOD2 (0.40) | NOD2NOD1NR1H2NR1H3MAPT | |
| SCHEMBL25308409 | 0.90 | NR1H2 (0.39) | NR1H2NR1H3 | |
| SCHEMBL12042731 | 0.84 | CYP4F2 (0.43) | NOD2NOD1NR1H2NR1H3MAPT | |
| SCHEMBL30527551 | 0.82 | NOD2 (0.34) | NOD2NOD1NR1H2NR1H3MAPT | |
| SCHEMBL25260653 | 0.82 | NOD2 (0.34) | NOD2NOD1NR1H2NR1H3MAPT | |
| SCHEMBL12042732 | 0.81 | NOD2 (0.52) | NOD2NOD1NR1H2MAPTKDM4E | |
| SCHEMBL12042743 | 0.81 | KDM1A (0.41) | NOD2NOD1MAPTF10KDM4E | |
| SCHEMBL3030334 | 0.80 | NOD2 (0.46) | NOD2NOD1NR1H2MAPTKDM4E | |
| SCHEMBL21685569 | 0.79 | NOD2 (0.45) | NOD2NOD1NR1H2MAPTKDM4E | |
| SCHEMBL1313682 | 0.79 | NOD2 (0.45) | NOD2NOD1NR1H2NR1H3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570679-B2 | STAT3 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-03-10 | — | — | US | disclosed |
| US-12522623-B2 | Small molecule STAT protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2024238598-A2 | STAT DEGRADERS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | UNIV MICHIGAN (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | UNIV MICHIGAN REGENTS (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3946619-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | The Regents Of The University Of Michigan (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020198435-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | STAT1, STAT3, JAK2 | NOD2 4369/4885NOD1 4460/4885NR1H2 4108/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | NOD2 1645/4885NOD1 2047/4885NR1H2 926/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | NOD2 3839/4885NOD1 4274/4885NR1H2 4275/4885 |
| US-12570679-B2 | STAT3 protein degraders | STAT3, JAK2, IL6ST | NOD2 3537/4885NOD1 3922/4885NR1H2 3486/4885 |
| US-20230295200-A1 | STAT5 and STAT6 Inhibitors and Uses Thereof | STAT6, STAT5B, STAT5A | NOD2 3130/4885NOD1 2789/4885NR1H2 1551/4885 |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | STAT1, STAT3, STAT5A | NOD2 4183/4885NOD1 4355/4885NR1H2 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.